Ibrahim Alradwan

597 total citations
18 papers, 443 citations indexed

About

Ibrahim Alradwan is a scholar working on Oncology, Biomedical Engineering and Molecular Biology. According to data from OpenAlex, Ibrahim Alradwan has authored 18 papers receiving a total of 443 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 7 papers in Biomedical Engineering and 5 papers in Molecular Biology. Recurrent topics in Ibrahim Alradwan's work include Nanoplatforms for cancer theranostics (5 papers), Nanoparticle-Based Drug Delivery (4 papers) and CAR-T cell therapy research (2 papers). Ibrahim Alradwan is often cited by papers focused on Nanoplatforms for cancer theranostics (5 papers), Nanoparticle-Based Drug Delivery (4 papers) and CAR-T cell therapy research (2 papers). Ibrahim Alradwan collaborates with scholars based in Saudi Arabia, Canada and United Kingdom. Ibrahim Alradwan's co-authors include Abdulaziz Almalik, Mohd Abul Kalam, Aws Alshamsan, Majed A. Majrashi, Nicola Tirelli, Ali H. Alhasan, Haitham AlRabiah, Ibrahim O. Alanazi, Waleed Alghamdi and Hicham Benabdelkamel and has published in prestigious journals such as Cancer Research, Scientific Reports and Journal of Controlled Release.

In The Last Decade

Ibrahim Alradwan

17 papers receiving 438 citations

Peers

Ibrahim Alradwan

BIOMA

Taehoon Sim South Korea

Yuan Yu China

Haijun Zhong China

Zahra Mirzaie Iran

Moonjeong Choi South Korea

Hussaini Syed Sha Qhattal United States

Guangxi Zhai China

Rassoul Dinarvand Iran

Golnaz Kamalinia Iran

Taehoon Sim South Korea

Ibrahim Alradwan

240 ×1.2

BIOMA

181 ×1.3

150 ×1.1

91 ×1.1

68 ×0.9

Citations per year, relative to Ibrahim Alradwan Ibrahim Alradwan (= 1×) peers Taehoon Sim

Countries citing papers authored by Ibrahim Alradwan

Since Specialization

Citations

This map shows the geographic impact of Ibrahim Alradwan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ibrahim Alradwan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ibrahim Alradwan more than expected).

Fields of papers citing papers by Ibrahim Alradwan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ibrahim Alradwan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ibrahim Alradwan. The network helps show where Ibrahim Alradwan may publish in the future.

Co-authorship network of co-authors of Ibrahim Alradwan

This figure shows the co-authorship network connecting the top 25 collaborators of Ibrahim Alradwan. A scholar is included among the top collaborators of Ibrahim Alradwan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ibrahim Alradwan. Ibrahim Alradwan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Alradwan, Ibrahim, et al.. (2025). Nanoparticles for Cancer Immunotherapy: Innovations and Challenges. Pharmaceuticals. 18(8). 1086–1086. 7 indexed citations

Almughem, Fahad A., et al.. (2025). Artificial intelligence revolution in drug discovery: A paradigm shift in pharmaceutical innovation. International Journal of Pharmaceutics. 680. 125789–125789. 4 indexed citations

Lip, HoYin, Ping Cai, Azhar Z. Abbasi, et al.. (2025). Mitigating radioresistance mechanisms by polymer-lipid manganese dioxide nanoparticles enhances immunogenic cell death and antitumor immune response to facilitate abscopal effect in breast tumor models. Drug Delivery and Translational Research. 16(1). 180–194. 2 indexed citations

Alradwan, Ibrahim, Nojoud AL Fayez, Alhassan H. Aodah, et al.. (2025). Strategic and Chemical Advances in Antibody–Drug Conjugates. Pharmaceutics. 17(9). 1164–1164. 2 indexed citations

Alradwan, Ibrahim, et al.. (2025). Empowering chemotherapy-induced antitumor immunity by multi-targeted synergistic combination nanomedicine for triple-negative breast cancer. Materials Today Bio. 35. 102445–102445.

Alshehri, Abdullah A., Ahmad M. Aldossary, Fahad A. Almughem, et al.. (2025). Unconventional Immunotherapies in Cancer: Opportunities and Challenges. Pharmaceuticals. 18(8). 1154–1154. 2 indexed citations

Abbasi, Azhar Z., Chunsheng He, HoYin Lip, et al.. (2024). Targeting DNA damage repair mechanism by using RAD50-silencing siRNA nanoparticles to enhance radiotherapy in triple negative breast cancer. Materials Today Bio. 28. 101206–101206. 4 indexed citations

Alradwan, Ibrahim, Tian Zhang, HoYin Lip, et al.. (2024). Nanoparticulate drug combination inhibits DNA damage repair and PD-L1 expression in BRCA-mutant and wild type triple-negative breast cancer. Journal of Controlled Release. 377. 661–674. 5 indexed citations

Alradwan, Ibrahim, Nojoud AL Fayez, Mohammad N. Alomary, et al.. (2024). Emerging Trends and Innovations in the Treatment and Diagnosis of Atherosclerosis and Cardiovascular Disease: A Comprehensive Review towards Healthier Aging. Pharmaceutics. 16(8). 1037–1037. 11 indexed citations

10.

Lip, HoYin, Azhar Z. Abbasi, Ibrahim Alradwan, et al.. (2023). Remodeling Tumor Immune Microenvironment by Using Polymer-Lipid-Manganese Dioxide Nanoparticles with Radiation Therapy to Boost Immune Response of Castration-Resistant Prostate Cancer. Research. 6. 247–247. 42 indexed citations

11.

Alradwan, Ibrahim, Tian Zhang, HoYin Lip, et al.. (2022). Abstract 5399: Synergistic combination nanomedicine of doxorubicin and oligo hyaluronic acid inhibits DNA damage repair and overcomes drug resistance in metastatic triple-negative breast cancer. Cancer Research. 82(12_Supplement). 5399–5399. 1 indexed citations

12.

Ahmed, Taksim, Brian Lu, HoYin Lip, et al.. (2022). Advances in Nanomedicine Design: Multidisciplinary Strategies for Unmet Medical Needs. Molecular Pharmaceutics. 19(6). 1722–1765. 11 indexed citations

13.

Zhang, Tian, Chaoping Fu, Ibrahim Alradwan, et al.. (2021). Targeting Signaling Pathways of Hyaluronic Acid and Integrin Receptors by Synergistic Combination Nanocomposites Inhibits Systemic Metastases and Primary Triple Negative Breast Cancer. Advanced Therapeutics. 4(6). 10 indexed citations

14.

Alanazi, Ibrahim O., Hicham Benabdelkamel, Waleed Alghamdi, et al.. (2020). A proteomic approach towards understanding crypoprotective action of Me2SO on the CHO cell proteome. Cryobiology. 94. 107–115. 2 indexed citations

15.

Almalik, Abdulaziz, Ibrahim Alradwan, Majed A. Majrashi, et al.. (2018). Cellular responses of hyaluronic acid-coated chitosan nanoparticles. Toxicology Research. 7(5). 942–950. 23 indexed citations

16.

Almalik, Abdulaziz, Ibrahim Alradwan, Mohd Abul Kalam, & Aws Alshamsan. (2017). Effect of cryoprotection on particle size stability and preservation of chitosan nanoparticles with and without hyaluronate or alginate coating. Saudi Pharmaceutical Journal. 25(6). 861–867. 92 indexed citations

17.

Almalik, Abdulaziz, Hicham Benabdelkamel, Afshan Masood, et al.. (2017). Hyaluronic Acid Coated Chitosan Nanoparticles Reduced the Immunogenicity of the Formed Protein Corona. Scientific Reports. 7(1). 10542–10542. 143 indexed citations

18.

Omar, Haneen, Jonas G. Croissant, Kholod Alamoudi, et al.. (2016). Biodegradable Magnetic Silica@Iron Oxide Nanovectors with Ultra-Large Mesopores for High Protein Loading, Magnetothermal Release, and Delivery. Journal of Controlled Release. 259. 187–194. 82 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact